Editor

Rachel E. Baron

Associate Attorney

Trump Administration Revives Possibility of MFN Drug Pricing: Key Implications for the Life Sciences Industry

On May 12, 2025, President Trump signed an Executive Order (“EO” or “Order”) “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” aimed at significantly reducing U.S. prescription drug prices by aligning them with the lowest prices paid by other developed nations.  According to the EO, drug manufacturers “deeply discount their products to access foreign markets…